84 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
in accountability with their interest in us being able to attract and retain the highest quality officers and avoiding litigation abuse resulting from … &A-related and other litigation so that claims against the officers continue even when identical claims against directors are dismissed. The board
8-K
EX-99.2
SYRS
Syros Pharmaceuticals Inc.
8 Jan 24
Regulation FD Disclosure
7:06am
of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding Syros’ clinical development plans, including
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
4:59pm
Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including
8-K
EX-99.2
eefztv7j4c10 alq5
6 Dec 23
Regulation FD Disclosure
7:05am
8-K
nrek6lo 54q1
2 Oct 23
Cost Associated with Exit or Disposal Activities
8:49am
8-K
g8ftty 4rkm
21 Jul 23
Termination of a Material Definitive Agreement
4:36pm
8-K
EX-99.2
73lwgnvje
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.2
bmxx865dl 4o9j97tp
12 Dec 22
Regulation FD Disclosure
7:48am
425
0ger6kb5reqf8tfvm2t
2 Sep 22
Business combination disclosure
4:03pm
8-K
ntwu35j
2 Sep 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm
424B3
ldpm55i1lo4bdx
8 Aug 22
Prospectus supplement
5:47pm
S-4/A
qcrgwbys 697x6l
1 Aug 22
Registration of securities issued in business combination transactions (amended)
9:01am
S-4
gzwe ge6va
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
425
iojsbq8ftkvh
5 Jul 22
Business combination disclosure
7:14am